SGMT – sagimet biosciences inc. (US:NASDAQ)
Stock Stats
News
Sagimet Announces Oral Presentation of Data from the Phase 2b FASCINATE-2 Study of Denifanstat in MASH at EASL International Liver Congress 2024
Sagimet Biosciences Announces Appointment of Thierry Chauche as Chief Financial Officer [Yahoo! Finance]
Sagimet Biosciences Announces Appointment of Thierry Chauche as Chief Financial Officer
Sagimet Biosciences Inc. (NASDAQ: SGMT) is now covered by analysts at HC Wainwright. They set a "buy" rating and a $32.00 price target on the stock.
Sagimet Biosciences' Denifanstat Imminent Phase 3: A Promising Investment Opportunity [Seeking Alpha]
Form 4 Sagimet Biosciences Inc. For: May 06 Filed by: Chauche Thierry
Form 3 Sagimet Biosciences Inc. For: May 06 Filed by: Chauche Thierry
Form 8-K Sagimet Biosciences Inc. For: May 03
Form ARS Sagimet Biosciences Inc. For: Dec 31
Form DEFA14A Sagimet Biosciences Inc.
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.